{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:25:21Z","timestamp":1777929921531,"version":"3.51.4"},"reference-count":27,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Palliative Medicine Reports"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Fatigue is a common and distressing symptom for palliative care patients. Although the current literature emphasizes nonpharmacological management, dexamethasone is reportedly used in clinical practice. This study helps to characterize its use, efficacy, and adverse effects in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To improve the evidence base by exploring the use, efficacy, and side effect profile of dexamethasone for fatigue management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This international multisite prospective observational case series assessed the benefit and adverse effects of dexamethasone at baseline (T0) and at five to seven days postbaseline (T1). Fatigue scores were assessed using the symptom assessment scale (SAS) and visual analogue fatigue scale (VAFS). Adverse events were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). The related samples Wilcoxon signed-rank test was used to compare before and after scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      All 18 patients (male\u2013female, 11:7) had advanced metastatic cancer with most in the deteriorating palliative care phase (56%). The most common dose of dexamethasone was 4\u2009mg daily orally. At T1 (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200912), improvement was seen in all measures of fatigue; the median SAS scores decreased from 7 to 5.5 (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.007), the median VAFS scores increased from 3 to 5 (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.126), and the median NCI-CTCAE fatigue scores were reduced from 3 to 2.5 (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.18). Dexamethasone was well tolerated; one participant experienced grade 3 delirium.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The small number of participants recruited for this study suggests that dexamethasone is not widely used specifically for fatigue. Our results suggest an improvement in fatigue scores from T0 to T1.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/pmr.2023.0050","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T11:10:56Z","timestamp":1710414656000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Use of Dexamethasone for Severe Fatigue in the Advanced Cancer Population: A Brief Report"],"prefix":"10.1177","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4503-0249","authenticated-orcid":false,"given":"Gemma","family":"Ingham","sequence":"first","affiliation":[{"name":"Department of Palliative Care, Prince of Wales Hospital, Randwick, New South Wales, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kat","family":"Urban","sequence":"additional","affiliation":[{"name":"Department of Palliative Care, Lismore Base Hospital, Lismore, New South Wales, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinyin","family":"Phyo","sequence":"additional","affiliation":[{"name":"Centre for Improving Palliative, Aged, and Chronic Care Through Clinical Research and Translation (IMPACCT), University of Technology, Sydney, New South Wales, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Hunt","sequence":"additional","affiliation":[{"name":"Centre for Improving Palliative, Aged, and Chronic Care Through Clinical Research and Translation (IMPACCT), University of Technology, Sydney, New South Wales, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penelope","family":"Tuffin","sequence":"additional","affiliation":[{"name":"Palliative Care Program, Pharmacist WA Country Health Service, Western Australia."},{"name":"Pharmacy and Palliative Care Departments, Fiona Stanley Hospital, Perth, Western Australia."},{"name":"Palliative Care Unit, Bethesda Hospital, Perth, Western Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davinia","family":"Seah","sequence":"additional","affiliation":[{"name":"Centre for Improving Palliative, Aged, and Chronic Care Through Clinical Research and Translation (IMPACCT), University of Technology, Sydney, New South Wales, Australia."},{"name":"Supportive and Palliative Care, Sacred Heart Health Service, Sydney, New South Wales, Australia."},{"name":"St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,3,13]]},"reference":[{"issue":"8","key":"e_1_3_5_2_2","first-page":"1012","article-title":"National comprehensive cancer network","volume":"13","author":"Berger AM","year":"2015","unstructured":"Berger AM, , Mooney K, , Alvarez-Perez A, et al. National comprehensive cancer network. Cancer-Related Fatigue, Version 2.2015. J Natl Compr Canc Netw, 2015; 13(8):1012\u20131039.","journal-title":"Cancer-Related Fatigue, Version 2.2015. J Natl Compr Canc Netw"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269216307085183"},{"issue":"6","key":"e_1_3_5_4_2","first-page":"1109","article-title":"The level of distress from fatigue reported in the final two months of life by a palliative care population; An Australian national prospective, consecutive case series","volume":"61","author":"Ingham G","year":"2020","unstructured":"Ingham G, , Urban K, , Allingham S, et al. The level of distress from fatigue reported in the final two months of life by a palliative care population; An Australian national prospective, consecutive case series. JPSM, 2020; 61(6):1109\u20131117.","journal-title":"JPSM"},{"key":"e_1_3_5_5_2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1023\/A:1008318932641","article-title":"Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey","volume":"11","author":"Stone P","year":"2000","unstructured":"Stone P, , Richardson A, , Ream E, et al. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Annu Oncol, 2000; 11:971\u2013975.","journal-title":"Annu Oncol"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1089\/pmr.2020.0005"},{"key":"e_1_3_5_7_2","unstructured":"Howell D Keller-Olaman S Oliver TK et al. A Pan-Canadian Practice Guideline: Screening Assessment and Care of Cancer-Related Fatigue in Adults with Cancer. Canadian Partnership Against Cancer (Cancer Journey Advisory Group) and the Canadian Association of Psychosocial Oncology: Toronto; February 2011."},{"key":"e_1_3_5_8_2","first-page":"23","article-title":"Pharmacological treatments for fatigue associated with palliative care: Executive summary of a Cochrane Collaboration systematic review","volume":"7","author":"Mucke M","year":"2016","unstructured":"Mucke M, , Mochamat, Cuhls H, et al. Pharmacological treatments for fatigue associated with palliative care: Executive summary of a Cochrane Collaboration systematic review. JCSM, 2016; 7:23\u201327.","journal-title":"JCSM"},{"key":"e_1_3_5_9_2","unstructured":"IMPACCT Rapid Program University of Technology Sydney. Available from: https:\/\/www.uts.edu.au\/research-and-teaching\/our-research\/impacct\/impacct-rapid-program [Last accessed: July 28 2023]."},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2012.9605"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2012.0111"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2013.0230"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2014-000699"},{"key":"e_1_3_5_14_2","unstructured":"REDCap. Available from: https:\/\/www.project-redcap.org [Last accessed July28 2023]."},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO;2-5"},{"key":"e_1_3_5_16_2","unstructured":"Shirley Ryan Abilitylab. Rehabilitation Measures Database Fatigue Severity Scale. 2016. Available from: https:\/\/www.sralab.org\/rehabilitation-measures\/fatigue-severity-scale [Last accessed: July28 2023]."},{"key":"e_1_3_5_17_2","first-page":"412964","article-title":"Reliability, responsiveness, and validity of the visual analog fatigue scale to measure exertion fatigue in people with chronic stroke: A preliminary study","volume":"2010","author":"Tseng BY","year":"2010","unstructured":"Tseng BY, , Gajewski BJ, , Kluding PM. Reliability, responsiveness, and validity of the visual analog fatigue scale to measure exertion fatigue in people with chronic stroke: A preliminary study. Stroke Res Treat, 2010; 2010:412964.","journal-title":"Stroke Res Treat"},{"key":"e_1_3_5_18_2","unstructured":"US Department of Health and Human Services. Common Terminology Criteria for Adverse Evets (CTCAE) version 5.0; 2017. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf [Last accessed: July28 2023]."},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.12968\/ijpn.2016.22.5.244"},{"key":"e_1_3_5_20_2","unstructured":"Jankowski C Carpenter KM Aranha O et al. NCCN Clinical Practice Guidelines in Oncology: Cancer-Related Fatigue. Version 2.2023."},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.02.016"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0260"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.4661"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1089\/pmr.2021.0053"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/1049909118797283"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269216320986717"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.142"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219872786"}],"container-title":["Palliative Medicine Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/pmr.2023.0050","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/pmr.2023.0050","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/pmr.2023.0050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:57:50Z","timestamp":1777679870000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/pmr.2023.0050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,13]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1089\/pmr.2023.0050"],"URL":"https:\/\/doi.org\/10.1089\/pmr.2023.0050","relation":{},"ISSN":["2689-2820","2689-2820"],"issn-type":[{"value":"2689-2820","type":"print"},{"value":"2689-2820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,13]]},"article-number":"pmr.2023.0050"}}